Secukinumab Provides Higher Symptomatic Improvement Versus Adalimumab in Psoriatic Arthritis- Comparative Effectiveness Up to 48 Weeks Assessed by two Matching-Adjusted indirect Comparisons
Abstract
Authors
H Thom M Hunger GF Rosal K Gandhi SM Jugl P Nash